The aim of this study was to investigate the prognostic value of hypermethylation of tumor suppressor genesin patients with non-small cell lung cancer (NSCLC). In samples from 34 lung patients with malignant pleuraleffusions, we used a methylation-specific polymerase chain reaction to detect aberrant hypermethylation of thepromoters of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT), p16INK4a, rasassociation domain family 1A (RASSF1A), apoptosis-related genes, death-associated protein kinase (DAPK),and retinoic acid receptor ß (RARß).There is no association between methylation status of five tumor suppressorgenes including MGMT, p16INK4a, RASSF1A, DAPK and RARß in pleural fluid DNA and clinicopathologicalparameters including clinical outcome. Aberrant promoter methylation of tumor suppressor genes in pleuralfluid DNA could not be a valuable prognostic marker of NSCLC patients with malignant pleural effusion.
(2007). Aberrant Promoter Methylation Profile in Pleural Fluid DNA and Clinicopathological Factors in Patients with Non-small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 8(2), 221-224.
MLA
. "Aberrant Promoter Methylation Profile in Pleural Fluid DNA and Clinicopathological Factors in Patients with Non-small Cell Lung Cancer". Asian Pacific Journal of Cancer Prevention, 8, 2, 2007, 221-224.
HARVARD
(2007). 'Aberrant Promoter Methylation Profile in Pleural Fluid DNA and Clinicopathological Factors in Patients with Non-small Cell Lung Cancer', Asian Pacific Journal of Cancer Prevention, 8(2), pp. 221-224.
VANCOUVER
Aberrant Promoter Methylation Profile in Pleural Fluid DNA and Clinicopathological Factors in Patients with Non-small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2007; 8(2): 221-224.
)